Introduction
============

Lung cancer is a leading cause of cancer-associated mortality worldwide and 80% of all lung cancer cases are non-small cell lung cancer (NSCLC) ([@b1-ol-0-0-9760]). Radical surgery is the standard treatment for NSCLC. However, a large number of patients experience disease progression, and therefore, a poor prognosis, within a short time following resection ([@b2-ol-0-0-9760]). Although several studies have been performed, the optimal prognostic factors for facilitating individualized treatments and an improvement in the prognosis of patients with NSCLC remain controversial ([@b3-ol-0-0-9760]). Therefore, it is of great importance to identify reliable preoperative prognostic variables to perform prognostic risk stratification and provide individualised treatment.

Previously, significant attention has been paid to the association between malignancies and coagulation ([@b4-ol-0-0-9760]). Among the coagulation factors, fibrinogen and D-dimer have been widely studied and are regarded as important prognostic factors in multiple types of solid tumour; including colorectal ([@b5-ol-0-0-9760]), uterine ([@b6-ol-0-0-9760]), cervical ([@b7-ol-0-0-9760]) and breast carcinoma ([@b8-ol-0-0-9760]). However, data regarding the prognostic significance of fibrinogen and D-dimer levels in NSCLC are lacking.

It has been widely recognized that cancer-related inflammatory variables, including the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and lymphocyte-monocyte ratio (LMR), serve an important role in the promotion of cell proliferation, angiogenesis and tumour metastasis, and in the inhibition of apoptosis ([@b9-ol-0-0-9760],[@b10-ol-0-0-9760]). Recently, an increasing number of studies have evaluated the prognostic significance of the combination of fibrinogen and NLR (COF-NLR) to predict postoperative survival in patients with oesophageal squamous cell and colon cancer ([@b11-ol-0-0-9760]--[@b13-ol-0-0-9760]). However, the prognostic significance of these two variables in patients with NSCLC has not been fully investigated.

Therefore, in the present study, a retrospective analysis was conducted to assess the prognostic relevance of preoperative coagulation factors and inflammatory indicators in a cohort of patients with non-metastatic NSCLC. Furthermore, a novel prognostic score was established by combining the optimal coagulation and inflammatory indicator status to assess the prognosis of patients with NSCLC that have undergone a complete resection.

Patients and methods
====================

### Patient selection

A total of 456 histopathologically-confirmed patients with NSCLC, who had undergone complete pulmonary resection and systematic lymphadenectomy with curative intent at the Department of Thoracic Surgery, the First Hospital of Qinhuangdao between January 2007 and June 2011, were retrospectively analysed. All patients provided written informed consent for the use of their information from the hospital database in the present study.

The eligibility criteria for the present study were as follows: Histopathologically-confirmed primary NSCLC without distant metastasis, complete surgical resection and systematic node dissection, no clinical evidence of infection or other inflammatory conditions, no autoimmune or coagulation disorders, no preoperative chemotherapy, radiotherapy or other treatment, complete clinicopathological records, including preoperative coagulation test, blood cell counts and complete follow-up as described below.

The preoperative evaluation included a physical examination, biochemical tests, coagulation tests, complete blood cell counts, flexible bronchoscopy, chest radiography, computed tomography (CT) scans, brain magnetic resonance imaging and radionuclide bone scans. The clinical stage was evaluated on the basis of the 7th edition of the Tumour-Node-Metastasis (TNM) classification for NSCLC by the Union for International Cancer Control ([@b14-ol-0-0-9760]).

### Coagulation measurements and blood cell count analysis

Fasting preoperative venous blood samples were obtained within one week prior to surgery and were stored in a blood collection tube containing EDTA. Preoperative plasma fibrinogen concentrations were assayed based on the Clauss clotting method using DADE Thrombin Reagent™ and a Sysmex CA-7000 analyser (Sysmex Corporation, Kobe, Japan) ([@b15-ol-0-0-9760]). The plasma D-dimer level was measured by Microparticle Enzyme-linked Immunoassay using AxSYM analyser (Abbott Laboratories, Chicago, IL, USA), according to the manufacturer\'s protocols.

Complete blood cell counts and differential white blood cell count analysis of all patients were performed using the Sysmex XE-5000 automated haematology analyser (cat. no., M349228; Sysmex Corporation, Kobe, Japan). The NLR was defined as the neutrophil count/the lymphocyte count. The PLR was defined as the platelet count/the lymphocyte count. The LMR was defined as the absolute lymphocyte count/the absolute monocyte count.

### Definition of COF-NLR score

The preoperative COF-NLR score was calculated by combining the fibrinogen and NLR, as previously described ([@b11-ol-0-0-9760]--[@b13-ol-0-0-9760]); patients with elevated plasma fibrinogen and NLR levels were assigned a score of 2, those that demonstrated elevated levels of one or neither were assigned a score of 1 and 0, respectively.

### Follow-up assessments

Following surgery, all patients received a follow-up evaluation via verbal or written correspondence or hospital visits every 3 months for the first year, every 6 months for the second year and subsequently every year until mortality or the final follow-up date (June 2016). Physical and laboratory examinations, as well as imaging studies, were performed at each hospital visit. Patient check-up included physical examination, tumor-marker examination, chest radiography, CT scans, neck and abdominal ultrasonography, and radionuclide bone scans when necessary to detect recurrence and/or metastasis. Overall survival (OS) time was calculated as the period from the date of surgery to the date of the patient\'s mortality or the final follow-up. The follow-up rate was 95.6% and the overall median follow-up time of the entire cohort was 42 months (range, 3--108 months).

### Statistical analysis

All statistical analyses were performed using SPSS software version 18.0 (SPSS, Inc., Chicago, IL, USA). The most appropriate cut-off values of the preoperative fibrinogen, NLR, PLR and LMR for survival prediction were calculated using receiver operating characteristic (ROC) curve analyses. The area under the curve (AUC) was determined to estimate the diagnostic accuracy. The χ^2^ test was used to analyse statistical associations between categorical variables. The 5-year OS rate was calculated by Kaplan-Meier analysis and compared using the log-rank test. Factors identified as potentially significant by univariate analyses (P\<0.05) were entered into a multivariate analysis with Cox regression model to identify the significant independent prognostic factors. The foundation of a novel prognostic score was based on the risk factors identified in the Cox proportional hazard model. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinicopathological variables of patients

A total of 456 patients with NSCLC with complete clinicopathological records were enrolled in the present study. The enrolled cohort consisted of 318 (69.7%) males and 138 (30.3%) females, with a median age of 61 years (range, 35--81 years). Of the enrolled patients, 387 (84.9%) underwent lobectomy and 69 (15.1%) underwent pneumonectomy. A total of 238 (52.2%) patients exhibited squamous cell carcinoma, 157 (34.4%) patients exhibited adenocarcinoma and 61 (13.4%) patients exhibited an unspecified type of post-operative pathological subtype. A total of 170 patients presented with stage I TNM, 101 with stage II and 185 with stage IIIA.

### Determination of the appropriate cut-off values for fibrinogen, NLR, PLR, LMR and D-dimer levels

The median value of plasma fibrinogen concentrations was 3.61 g/l. The optimal fibrinogen cut-off point was 3.77 g/l, according to the ROC analysis, with an AUC of 0.635 (P\<0.001; [Fig. 1A](#f1-ol-0-0-9760){ref-type="fig"}). The median value of NLR was 2.21. The optimal cut-off value was 2.28, according to the ROC analysis, with an AUC of 0.627 (P\<0.001; [Fig. 1B](#f1-ol-0-0-9760){ref-type="fig"}). The median value of PLR was 125.45. The optimal cut-off point was 106.24, according to the ROC analysis, with an AUC of 0.588 (P\<0.001; [Fig. 1C](#f1-ol-0-0-9760){ref-type="fig"}). The median value of LMR was 3.62. The optimal cut-point was 3.70, according to the ROC analysis, with an AUC of 0.618 (P\<0.001; [Fig. 1D](#f1-ol-0-0-9760){ref-type="fig"}).

Based on these cut-off point values, patients were divided into two groups for each measured variable: Fibrinogen \[low (≤3.77 g/l, n=246) and high (\>3.77 g/l, n=210)\], NLR \[low (≤2.28, n=242) and high (\>2.28, n=214)\], PLR \[low (≤106.24, n=145) and high (\>106.24, n=311)\], and LMR \[low (≤3.7, n=240) and high (\>3.7, n=216)\].

Furthermore, the reference value for D-dimer was ≤500 ng/ml. Among the enrolled patients, 325 (71.3%) demonstrated low plasma D-dimer levels (D-dimer ≤500 ng/ml) and 131 (28.7%) demonstrated high plasma D-dimer levels (D-dimer \>500 ng/ml). Patients were therefore categorized into two groups according to plasma D-dimer levels: Low (D-dimer ≤500 ng/ml) and high (D-dimer \>500 ng/ml).

### Association between preoperative fibrinogen or D-dimer levels and clinicopathological variables

The associations between preoperative plasma fibrinogen or D-dimer levels and the clinicopathological variables of patients with NSCLC are presented in [Table I](#tI-ol-0-0-9760){ref-type="table"}. These results revealed that high preoperative plasma fibrinogen levels were significantly associated with sex (P\<0.001), age (P=0.018), smoking history (P\<0.001), lesion type (P=0.001), T stage (P\<0.001), pathological stage (P=0.002), NLR (P\<0.001), PLR (P\<0.001) and LMR (P\<0.001). However, no statistically significant associations were identified between preoperative plasma fibrinogen level and tumour location or lymph node metastasis (P\>0.05).

There were also significant associations between D-dimer level and age (P=0.035), T stage (P=0.011), pathological stage (P=0.001) and NLR (P=0.005). However, no significant associations were identified between D-dimer level and sex, smoking history, tumour location, lesion type, lymph node metastasis, PLR or LMR (all P\>0.05; [Table I](#tI-ol-0-0-9760){ref-type="table"}).

### Prognostic significance of preoperative coagulation and inflammatory indicators

Kaplan-Meier analyses and log-rank tests were performed to determine the prognostic value of coagulation factors and inflammatory indicators in predicting patient 5-year OS rates. The data demonstrated that the 5-year OS rate and median OS time of the fibrinogen-low group were significantly higher than those of the fibrinogen-high group \[43.5 vs. 29.0% (48.0 vs. 26.0 months), P\<0.001; [Fig. 2A](#f2-ol-0-0-9760){ref-type="fig"}\]. The 5-year OS rate and median OS time of the D-dimer-low group was significantly higher than those of the D-dimer-high group \[40.3 vs. 28.2% (41.0 vs. 28.0 months), P=0.004; [Fig. 2B](#f2-ol-0-0-9760){ref-type="fig"}\]. The 5-year OS rate and median OS time of the NLR-low group were significantly higher than those of the NLR-high group \[43.4 vs. 29.4% (47.0 vs 28.0 months), P\<0.001; [Fig. 2C](#f2-ol-0-0-9760){ref-type="fig"}\]. The 5-year OS rate and median OS time of the PLR-low group were significantly higher than those of the PLR-high group \[44.1 vs. 33.4% (41.0 vs. 35.0 months), P=0.019; [Fig. 2D](#f2-ol-0-0-9760){ref-type="fig"}\]. In addition, the 5-year OS probability and median OS time of the LMR-high group were also significantly higher than those of the LMR-low group \[41.2 vs. 32.9% (43.0 vs. 30.0 months), P=0.003; [Fig. 2E](#f2-ol-0-0-9760){ref-type="fig"}\].

### Univariate and multivariate survival analyses of independent prognostic variables in patients with NSCLC

To further identify predictors of postoperative OS, clinicopathological variables, including coagulation and inflammatory indicators, were evaluated using univariate and multivariate analyses. Univariate analyses for OS with a log-rank test demonstrated that smoking history (P=0.023), lesion type (P=0.030), resection type (P=0.018), T stage (P=0.025), lymph node metastasis (P\<0.001), plasma fibrinogen (P\<0.001), D-dimer (P=0.004), NLR (P\<0.001), PLR (P=0.019) and LMR (P=0.003) were significantly associated with patient prognosis ([Table II](#tII-ol-0-0-9760){ref-type="table"}).

All 10 factors indicated as significant by univariate analyses were further subjected to multivariate analyses with a Cox proportional hazards model to determine the independent prognostic factors associated with OS. The results indicated that lymph node metastasis (P\<0.001), plasma fibrinogen level (P=0.024) and NLR (P=0.028) were significant independent prognostic variables associated for a poor OS rate ([Table III](#tIII-ol-0-0-9760){ref-type="table"}).

### Prognostic analysis based on COF-NLR score for NSCLC patients

According to the grading system of the COF-NLR score, 168 (36.8%) patients had a COF-NLR score of 0, 152 (33.3%) patients had a COF-NLR score of 1 and 136 (29.8%) patients had a COF-NLR score of 2. The 5-year OS rates for patients with COF-NLR scores of 0, 1 and 2 were 50.0, 34.2 and 23.5%, respectively (P\<0.001; [Fig. 3](#f3-ol-0-0-9760){ref-type="fig"}). Therefore, it was possible to classify the patients into three distinct prognostic groups using the preoperative COF-NLR score.

### Prognostic significance of preoperative COF-NLR in subgroups of patients

The results of the present study demonstrated that preoperative COF-NLR was significantly associated with OS. To further evaluate the prognostic value of COF-NLR in subgroups of patients with NSCLC, the patients were further classified according to histopathological subtype, lymph node status and pathological stage. The results revealed that, in the squamous cell cancer subgroup, COF-NLR exhibited notable prognostic value in predicting poorer OS rates ([Fig. 4A](#f4-ol-0-0-9760){ref-type="fig"}) and was also effective in patients with adenocarcinoma ([Fig. 4B](#f4-ol-0-0-9760){ref-type="fig"}). In addition, COF-NLR was a prognostic indicator for OS in patients with or without lymph node metastasis ([Fig. 5](#f5-ol-0-0-9760){ref-type="fig"}). Furthermore, when stratifying the patients based on clinical stage, COF-NLR also retained its predictive value for patients with pathological stage I, II or IIIA tumours ([Fig. 6](#f6-ol-0-0-9760){ref-type="fig"}). Therefore, it appears that COF-NLR may serve as a powerful prognostic factor for categorising patients with NSCLC into different risk subgroups.

Discussion
==========

Establishing one optimal preoperative prognostic factor for facilitating individual risk stratification and management is critical for improving outcomes for patients with NSCLC. Although numerous studies have been conducted to search for predictors, there is a continuing debate regarding the optimal preoperative prognostic factor for NSCLC ([@b16-ol-0-0-9760]--[@b18-ol-0-0-9760]). The activated coagulation system and systematic inflammatory response serve important functions in tumour invasion, angiogenesis promotion, metastasis and poor prognosis in several types of malignant disease ([@b3-ol-0-0-9760],[@b19-ol-0-0-9760],[@b20-ol-0-0-9760]). Therefore, the present study evaluated the clinical and prognostic value of preoperative coagulation factor levels (fibrinogen and D-dimer) and inflammatory variables (NLR, PLR and LMR), and assessed the prognostic value of combining fibrinogen with NLR in NSCLC as a novel, single prognostic model.

Tumour-mediated activation of the coagulation pathway is associated with tumour growth, angiogenesis promotion and metastasis ([@b21-ol-0-0-9760]). Fibrinogen and D-dimer are key components of the coagulation system. Fibrinogen, an acute-phase reactant glycoprotein, is involved in the thrombin transformation of the coagulation cascade and clot formation ([@b22-ol-0-0-9760]). D-dimer, a stable end product of fibrin degradation, is associated with the presence of venous thromboembolism in cancer patients ([@b23-ol-0-0-9760]). The present study analysed the association between preoperative fibrinogen, D-dimer and clinicopathological variables. It identified that elevated fibrinogen was associated with the tumour size (T) and TNM stages, which is consistent with the findings of Zeng *et al* ([@b3-ol-0-0-9760]). Furthermore, the association between preoperative elevated D-dimer levels and clinicopathological variables in NSCLC was reported for the first time, and the results demonstrated that elevated D-dimer levels were also associated with the T and TNM stages. In addition, the results of multivariate prognostic analyses revealed that preoperative elevated fibrinogen levels, not D-dimer levels, was an independent prognostic factor for patients with NSCLC. However, the mechanism for this effect remains to be elucidated. A previous study demonstrated that interleukin-6 produced by cancer cells could stimulate the secretion of fibrinogen in lung cancer ([@b24-ol-0-0-9760]). Furthermore, elevated fibrinogen can promote angiogenesis and facilitate tumour cell metastasis by serving as an extracellular matrix for migration ([@b25-ol-0-0-9760],[@b26-ol-0-0-9760]).

Imbalance in the host systematic inflammatory system serves an important role in tumour progression, proliferation and metastasis ([@b27-ol-0-0-9760]). A systematic inflammatory response causes variations in the number of circulating white blood cells, including neutrophils, lymphocytes and monocytes, during cancer progression ([@b11-ol-0-0-9760]). Previous studies have reported that three haematological indices, as the ratio of absolute counts of these three white cell constituents (NLR, PLR and LMR) were independent prognostic factors in NSCLC ([@b28-ol-0-0-9760]), gastric cancer ([@b29-ol-0-0-9760]) and oesophageal cancer ([@b30-ol-0-0-9760]). The present study examined the prognostic value of preoperative NLR, PLR and LMR in patients with NSCLC. The results demonstrated that a decreased 5-year OS rate in patients with NSCLC was associated with a higher NLR and PLR, and a lower LMR. In multivariate survival analysis, a higher preoperative NLR was demonstrated to be an independent prognostic factor for patients with NSCLC. Neutrophils promote tumour angiogenesis by releasing angiogenic factors, including vascular endothelial growth factor, angiopoietin-1 and fibroblast growth factor-2 ([@b31-ol-0-0-9760]). Lymphocytes can induce the suppression of antitumor immunity by releasing inhibitory immunological mediators, including interleukin-10 and transforming growth factor-β ([@b32-ol-0-0-9760]). This may explain why an elevated NLR was associated with poorer survival rates in patients with NSCLC.

The present study also investigated the association between the three inflammatory indictors and coagulation factors, and demonstrated that higher fibrinogen levels were associated with NLR, PLR and LMR, whereas elevated D-dimer levels were only associated with higher NLR. Host inflammatory (monocyte/macrophage) cell-mediated triggering of clotting activation may be one possible mechanism in NSCLC ([@b33-ol-0-0-9760]). However, the mechanism behind activation of coagulation due to an increase in host inflammatory response requires further study.

As fibrinogen and NLR were demonstrated to be independent prognostic factors for patients with NSCLC in the present study, COF-NLR may aid the identification of patients with a poor prognosis following surgery and the provision of individualised treatment. In previous studies, the combined prognostic value of fibrinogen with inflammatory indicators has been discussed for gastric ([@b11-ol-0-0-9760]), bladder ([@b34-ol-0-0-9760]), hepatocellular ([@b13-ol-0-0-9760]) and oesophageal squamous cell carcinoma ([@b35-ol-0-0-9760]). However, the prognostic significance of COF-NLR has not been reported in NSCLC and this was investigated in the present study. Based on the preoperative COF-NLR score proposed in the current study, patients with NSCLC were divided into three distinct risk groups. The prognostic value of COF-NLR for histological subtype, lymph node metastasis and pathological stage subgroups was also investigated. The COF-NLR maintained its prognostic value in OS prediction for all subgroups of patients with NSCLC, indicating the reliable prognostic value of COF-NLR. To the best of our knowledge, the present study was the first to investigate the prognostic value of COF-NLR in patients with NSCLC. Considering that fibrinogen and NLR are markers that can be readily evaluated in conventional blood analyses ([@b11-ol-0-0-9760]), the preoperative assessment of COF-NLR may be suitable as a reliable prognostic tool for patients with NSCLC; the lower-scoring COF-NLR groups are associated with an improved prognosis compared with the higher-scoring COF-NLR groups.

However, there are certain limitations to the present study. To begin with, this retrospective study was conducted by a single institution. Secondly, all data were selected from one relatively small sample of patients, and a control arm was not set for validation. Therefore, the preoperative prognostic significance of COF-NLR in patients with NSCLC should be further strengthened in a larger, multicentre prospective study.

In conclusion, in the present study it was identified that, of the coagulation and inflammatory indicators, preoperative fibrinogen and NLR were independent prognostic predictors for NSCLC. A novel prognostic factor was further proposed, based on the combination of fibrinogen with the NLR from blood specimen analysis (COF-NLR), and was demonstrated to have prognostic predictive potential for patients with NSCLC. In the future, by adding this prognostic factor to clinical work, it may be possible to make insightful preoperative prognostic predictions and customise individual treatment plans for patients with NSCLC.
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![Receiver operating characteristic curve analyses for the cut-off values of (A) fibrinogen, (B) NLR, (C) PLR and (D) LMR in patients with NSCLC. NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio; AUC, area under the curve; CI, confidence interval; NSCLC, non-small cell lung cancer. ROC analysis was used to calculate P-values.](ol-17-02-1435-g00){#f1-ol-0-0-9760}

![Kaplan-Meier survival curves for OS according to preoperative (A) fibrinogen, (B) D-dimer, (C) NLR, (D) PLR and (E) LMR in patients with NSCLC. OS, overall survival; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio; COF-NLR, combination of fibrinogen and NLR; NSCLC, non-small-cell lung cancer. Kaplan-Meier survival analysis with the log-rank test was used to calculate P-values.](ol-17-02-1435-g01){#f2-ol-0-0-9760}

![Kaplan-Meier survival curve for overall survival according to the preoperative COF-NLR score in patients with NSCLC. COF-NLR, combination of fibrinogen and NLR; NSCLC, non-small cell lung cancer. Kaplan-Meier survival analysis with the log-rank test was used to calculate P-values.](ol-17-02-1435-g02){#f3-ol-0-0-9760}

![Kaplan-Meier survival curve for overall survival according to the COF-NLR score in (A) patients with primary squamous cell carcinoma and (B) patients with adenocarcinoma. COF-NLR, combination of fibrinogen and NLR. Kaplan-Meier survival analysis with the log-rank test was used to calculate P-values.](ol-17-02-1435-g03){#f4-ol-0-0-9760}

![Kaplan-Meier survival curves for overall survival according to the COF-NLR score in (A) N0 NSCLC patients and (B) N1-N3 NSCLC patients. COF-NLR, combination of fibrinogen and NLR; NSCLC, non-small cell lung cancer. Kaplan-Meier survival analysis with the log-rank test was used to calculate P-values.](ol-17-02-1435-g04){#f5-ol-0-0-9760}

![Kaplan-Meier survival curves for overall survival according to COF-NLR score of (A) pathological stage I NSCLC patients, (B) stage II NSCLC patients and (C) stage IIIA NSCLC patients. COF-NLR, combination of fibrinogen and NLR; NSCLC, non-small cell lung cancer. Kaplan-Meier survival analysis with the log-rank test was used to calculate P-values.](ol-17-02-1435-g05){#f6-ol-0-0-9760}

###### 

The association of preoperative plasma fibrinogen and D-dimer levels with clinicopathological variables in patients with NSCLC.

                                Fibrinogen                         D-dimer                                     
  ----------------------- ----- ------------ ------------ -------- --------- ------------ ----------- -------- -------
  Sex                                                     21.273   \<0.001                            0.355    0.551
    Male                  318   149 (46.9)   169 (53.1)                      224 (70.4)   94 (29.6)            
    Female                138   97 (70.3)    41 (29.7)                       101 (73.2)   37 (26.8)            
  Age (years)                                             5.552    0.018                              4.468    0.035
    \<61                  227   135 (59.5)   92 (40.5)                       172 (75.8)   55 (24.2)            
    ≥61                   229   111 (48.5)   118 (51.5)                      153 (66.8)   76 (33.2)            
  Smoking history                                         23.999   \<0.001                            0.552    0.457
    None                  151   106 (70.2)   45 (29.8)                       111 (73.5)   40 (26.5)            
    Yes                   305   140 (45.9)   165 (54.1)                      214 (70.2)   91 (29.8)            
  Tumor location                                          0.241    0.624                              0.355    0.551
    Left                  192   101 (52.6)   91 (47.4)                       134 (69.8)   58 (30.2)            
    Right                 264   145 (54.9)   119 (45.1)                      191 (72.3)   73 (27.7)            
  Lesion type                                             10.666   0.001                              2.816    0.093
    Peripheral            315   186 (59.0)   129 (41.0)                      232 (73.7)   83 (26.3)            
    Central               141   60 (42.6)    81 (57.4)                       93 (66.0)    48 (34.0)            
  T stage                                                 41.301   \<0.001                            8.992    0.011
    T1                    150   111 (74.0)   39 (26.0)                       115 (76.7)   35 (23.3)            
    T2                    258   121 (46.9)   137 (53.1)                      184 (71.3)   74 (28.7)            
    T3-4                  48    14 (29.2)    34 (70.8)                       26 (54.2)    22 (45.8)            
  Lymph node metastasis                                   0.120    0.729                              2.507    0.113
    No                    232   127 (54.7)   105 (45.3)                      173 (74.6)   59 (25.4)            
    Yes                   224   119 (53.1)   105 (46.9)                      152 (67.9)   72 (32.1)            
  Pathological stage                                      12.467   0.002                              13.297   0.001
    I                     170   109 (64.1)   61 (35.9)                       138 (81.2)   32 (18.8)            
    II                    101   44 (43.6)    57 (56.4)                       64 (63.4)    37 (36.6)            
    IIIA                  185   93 (50.3)    92 (49.7)                       123 (66.5)   62 (33.5)            
  NLR                                                     49.700   \<0.001                            7.863    0.005
    Low                   242   168 (69.4)   74 (30.6)                       186 (76.9)   56 (23.1)            
    High                  214   78 (36.4)    136 (63.6)                      139 (65.0)   75 (35.0)            
  PLR                                                     19.301   \<0.001                            2.895    0.089
    Low                   145   100 (69.0)   45 (31.0)                       111 (76.6)   34 (23.4)            
    High                  311   146 (46.9)   165 (53.1)                      214 (68.8)   97 (31.2)            
  LMR                                                     30.757   \<0.001                            0.706    0.401
    Low                   240   100 (41.7)   140 (58.3)                      167 (69.6)   73 (30.4)            
    High                  216   146 (67.6)   70 (32.4)                       158 (73.1)   58 (26.9)            

NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio. χ^2^ test was used to calculate the P-values.

###### 

Univariate survival analysis of prognostic factors by the Kaplan-Meier method in patients with NSCLC.

  Clinicopathological variable   n     5-year OS rate, %   MST    χ^2^ value   P-value
  ------------------------------ ----- ------------------- ------ ------------ ---------
  Sex                                                             0.782        0.377
    Male                         318   36.5                36.0                
    Female                       138   37.7                39.0                
  Age, years                                                      1.404        0.236
    \<61                         227   37.4                40.0                
    ≥61                          229   36.2                33.0                
  Smoking history                                                 5.155        0.023
    None                         151   43.0                44.0                
    Yes                          305   33.8                33.0                
  Histological type                                               0.528        0.768
    Squamous                     238   35.7                35.0                
    Adenocarcinoma               157   37.6                39.0                
    Others                       61    39.3                32.0                
  Tumor location                                                  1.418        0.234
    Left                         192   34.4                34.0                
    Right                        264   38.6                39.0                
  Lesion type                                                     4.735        0.030
    Peripheral                   315   39.7                41.0                
    Central                      141   30.5                32.0                
  Resection type                                                  5.592        0.018
    Lobectomy                    387   38.8                39.0                
    Pneumonectomy                69    26.1                30.0                
  T stage                                                         7.374        0.025
    T1                           150   39.3                41.0                
    T2                           258   38.5                38.0                
    T3-4                         48    20.8                25.0                
  Lymph node metastasis                                           46.357       \<0.001
    No                           232   50.0                58.0                
    Yes                          224   23.2                27.0                
  Fibrinogen level                                                15.413       \<0.001
    Low                          246   43.5                48.0                
    High                         210   29.0                26.0                
  D-dimer                                                         8.072        0.004
    Low                          325   40.3                41.0                
    High                         131   28.2                28.0                
  NLR                                                             15.979       \<0.001
    Low                          242   43.4                47.0                
    High                         214   29.4                28.0                
  PLR                                                             5.503        0.019
    Low                          145   44.1                41.0                
    High                         311   33.4                35.0                
  LMR                                                             8.967        0.003
    Low                          240   32.9                30.0                
    High                         216   41.2                43.0                

OS, overall survival; MST, median survival time; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio. Kaplan-Meier survival analysis with the log-rank test was used to calculate P-values.

###### 

Multivariate survival analysis of independent prognostic factors by the Cox proportional hazard model in patients with NSCLC.

  Clinicopathological variable   B        SE      Wald     P-value   HR      95% CI
  ------------------------------ -------- ------- -------- --------- ------- --------------
  Smoking history                −0.066   0.132   0.249    0.618     0.936   0.722\~1.214
  Lesion type                    −0.087   0.135   0.412    0.521     0.917   0.703\~1.195
  Resection type                 0.138    0.163   0.717    0.397     1.148   0.834\~1.579
  T stage                        0.033    0.095   0.119    0.730     1.033   0.858\~1.244
  Lymph node metastasis          0.754    0.118   41.020   \<0.001   2.125   1.687\~2.676
  Fibrinogen level               0.299    0.132   5.119    0.024     1.348   1.041\~1.746
  D-dimer                        0.238    0.123   3.775    0.058     1.269   0.998\~1.614
  NLR                            0.295    0.134   4.858    0.028     1.344   1.033\~1.747
  PLR                            0.044    0.132   0.112    0.738     1.045   0.806\~1.355
  LMR                            −0.085   0.128   0.437    0.509     0.919   0.715\~1.181

NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio; HR, hazard ratio; CI, confidence interval. Multivariate survival analysis with Cox regression model was used to calculate P-values.
